Atlas Trials

Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCL

Clinical trial NCT04624958 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04624958
Sponsor
Sun Yat-sen University
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Mantle Cell LymphomaNewly-diagnosed Mantle Cell Lymphoma
Start date
2020-12-01
Primary completion
2024-12-01
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.